Matej Mikulic
Research expert covering health, pharma & medtech
U.S. pharmaceutical industry - statistics & facts
The United States is the single largest national pharmaceutical market in the world, accounting for over half of global prescription drug sales by value. Net medicine spending reached approximately 487 billion U.S. dollars in 2024 and is forecast to surpass 600 billion dollars by the end of the decade. Revenue is concentrated in specialty and chronic-care therapy areas — led by oncology, followed by immunology and anti-diabetes — with the GLP-1 class emerging as a major commercial force: Mounjaro and Ozempic now rank among the top five drugs by U.S. revenue. This scale is sustained by heavy R&D reinvestment — roughly one-fifth of global revenues — and a pipeline that continues to deliver, with novel drug approvals remaining robust and orphan designations elevated, reflecting sustained activity across rare diseases and specialty medicine.
High spending, shifting payer dynamics
Per capita drug expenditure in the U.S. runs far above the comparable high-income country average, financed through a mix of private insurance, Medicare, Medicaid, and out-of-pocket payments — with Medicare's share more than tripling over the period shown. Generics and biosimilars now deliver hundreds of billions in annual savings, yet branded products continue to capture a growing share of total spending, while Medicare-negotiated price reductions on major drugs are beginning to reshape the pricing landscape.
Growth is decelerating but divergent
Market revenue growth is forecast to ease gradually through the end of the decade, but company-level trajectories diverge sharply. Eli Lilly — propelled by its GLP-1 franchise — leads with a forecast five-year growth rate above 14 percent, far ahead of peers such as Amgen and Merck. Major patent expirations — Keytruda, Eliquis, and Stelara together represent over 70 billion U.S. dollars in peak annual sales — will determine which companies successfully reload their portfolios.
Strategic outlook
The U.S. will remain the world's most consequential pharmaceutical profit pool, but value creation is being reshaped by three converging pressures.
First, a patent cliff: between 2025 and 2028, blockbusters targeting complex biologics face loss of exclusivity. Unlike the small-molecule cliffs of the early 2010s, biosimilar erosion will unfold more slowly but with deeper structural consequences for originator margins. Second, policy-driven price compression on two fronts. The IRA's Medicare negotiation provisions are estimated to save around 320 billion U.S. dollars through 2031, while the administration's Most-Favored-Nation executive order is pushing manufacturers to align U.S. prices with the lowest offered to comparable nations — with major companies already signing binding agreements and the TrumpRx platform extending price concessions directly to patients. Third, trade policy uncertainty. Tariffs of up to 100 percent on imported branded drugs and sharply higher levies on Chinese-sourced APIs could raise input costs at the very moment margins are already under pressure.
Taken together, these forces compress the industry from both the revenue and cost sides simultaneously — a configuration the sector has not faced before. Companies with differentiated pipelines, scaled metabolic franchises, and domestic manufacturing optionality are best positioned to navigate this triple squeeze. Those still dependent on mature blockbusters approaching patent expiry face the most acute strategic risk.
